An antibody's increased tendency to bind itself at high concentrations limits its stability. As such, scientists must carefully characterize self-interaction when selecting molecules for ...

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing ...

Bio‑Sourcing and Zerion Pharma A/S today announce that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody used to treat breast cancer, has been awarded ...

Coriolis is also launching two novel platform services for developability assessment and pre-formulation screening, designed to de-risk and accelerate the path of antibody drug candidates to the ...

The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

The biopharmaceutical industry faces a continuous pressure to deliver innovative treatments in a safe and appropriate manner, including the rapidly growing area of therapeutic antibodies. However, the ...

To optimize the final formulation for a drug, it must meet many criteria beyond producing a safe and effective product. For example, it must be stable and amenable to various manufacturing steps, such ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group announced today that the company has accelerated development of a nebulised formulation of its neutralising antibody cocktail treatment, to ...

With the mix of mutations in omicron raising fears the new COVID-19 virus will evade our existing defenses, Celltrion is stepping up work on a nebulized cocktail it thinks may remain effective against ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group announced today it has submitted an Investigational New Drug (IND) application to conduct a global Phase III clinical trial evaluating the ...